Following the introduction of Indonesia’s Universal Health Coverage (UHC) policy, the drug procurement mechanism shifted to an e-catalog system. However, the consequences of this transition for the country’s pharmaceutical industry remain uncertain and insufficiently examined. This study aims to evaluate how the UHC policy has influenced drug pricing practices within Indonesia’s pharmaceutical sector. Data were collected from three pharmaceutical companies that successfully won e-catalog tenders. Drug prices for 2013 were sourced from the Drug Price Ceiling List, while those for 2015 and 2018 were obtained from the e-catalogue listings. The price data were compared across these years to identify trends and measure the extent of price variations. A price index analysis, adapted from the Median Price Ratio (MPR) method, was applied to compare 2013 prices with regional drug prices in 2015 and 2018 using Microsoft Excel. The findings revealed both increases and decreases in drug prices between the pre-UHC period (2013) and the post-UHC periods (2015 and 2018). Price increases ranged from 0.01–6.15 in 2015 and 0.01–6.46 in 2018, while reductions varied between 0.04–0.75 in 2015 and 0.01–0.83 in 2018. Drug pricing patterns in Indonesia showed notable fluctuations from the pre-UHC period (2013) through the UHC implementation years (2015 and 2018), with both upward and downward price adjustments observed.
